Evogene Ltd. (EVGN) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EVGN Revenue Growth
EVGN Revenue Analysis (2013–2024)
As of May 8, 2026, Evogene Ltd. (EVGN) generated trailing twelve-month (TTM) revenue of $5.3 million, reflecting significant decline in growth of -82.1% year-over-year. The most recent quarter (Q3 2025) recorded $312,000 in revenue, down 64.7% sequentially.
Looking at the longer-term picture, EVGN's 5-year compound annual growth rate (CAGR) stands at +62.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $17.6 million in 2013.
When compared to Healthcare sector peers including PGEN (+59.2% YoY), CDNA (+19.2% YoY), and NTRA (+35.9% YoY), EVGN has underperformed the peer group in terms of revenue growth. Compare EVGN vs PGEN →
EVGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EVGNCurrent | $5M | -82.1% | +62.4% | -255.4% | |
 PGEN | $4M | +59.2% | -34.3% | -3440.2% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 CTVA | $17.4B | +6.3% | +4.1% | 15.1% | |
 FMC | $3.5B | -16.6% | -5.7% | -54.4% |
EVGN Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $8.5M | +50.9% | $3.4M | 39.8% | $-21,734,000 | -255.4% |
| 2023 | $5.6M | +236.7% | $1.4M | 24.8% | $-26,391,000 | -467.9% |
| 2022 | $1.7M | +80.1% | $-1,774,000 | -105.9% | $-29,715,000 | -1774.0% |
| 2021 | $930K | -10.6% | $-2,071,000 | -222.7% | $-31,490,000 | -3386.0% |
| 2020 | $1.0M | +38.1% | $-2,261,000 | -217.4% | $-26,835,000 | -2580.3% |
| 2019 | $753K | -56.9% | $-2,350,000 | -312.1% | $-22,740,000 | -3019.9% |
| 2018 | $1.7M | -48.3% | $-1,564,000 | -89.5% | $-21,254,000 | -1216.6% |
| 2017 | $3.4M | -48.3% | $-1,300,000 | -38.5% | $-21,785,000 | -644.3% |
| 2016 | $6.5M | -41.2% | $-778,000 | -11.9% | $-21,089,000 | -322.5% |
| 2015 | $11.1M | -23.3% | $1.4M | 12.6% | $-17,921,000 | -161.0% |
See EVGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEVGN — Frequently Asked Questions
Quick answers to the most common questions about buying EVGN stock.
Is EVGN's revenue growth accelerating or slowing?
EVGN revenue declined -82.1% year-over-year, contrasting with the 5-year CAGR of +62.4%. TTM revenue fell to $5M. This reverses the prior growth trend.
What is EVGN's long-term revenue growth rate?
Evogene Ltd.'s 5-year revenue CAGR of +62.4% reflects the variable expansion pattern. Current YoY growth of -82.1% is below this long-term average.
How is EVGN's revenue distributed by segment?
EVGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.